⌘K
Loading ticker…
As of 2026-08-24, Ultragenyx Pharmaceutical Inc. (RARE) has a 3-month relative strength percentile of 67 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 49. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 0.71×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
RARE is held by 23 ETFs as of May 2026. Top owner: SCHA at 0.05% weight, $11M notional. Top 3 carry $21M.
Held by 63 ETFs · $325M across latest filings · largest weight 3.03% (TMFS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $11M | — |
| VHTVanguard Health Care ETF | 0.03% | $6M | — |
| VONGVanguard Russell 1000 Growth ETF | 0.01% | $4M | — |
| TMFS | 3.03% | $2M | +0.21 pp |
| SCHBSchwab U.S. Broad Market ETF |
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $1M |
| — |
| ESML | 0.06% | $1M | +0.02 pp |
| GNOM | 2.25% | $1M | +0.47 pp |
| ONEQ | 0.01% | $779K | — |
| EQAL | 0.09% | $732K | +0.04 pp |
| ESGV | 0.00% | $497K | — |
Showing 10 of 23 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RARE Jan avg: -0.75% median: 0.06% win: 50% σ: 5.46% n: 4 2022-04-12 → 2026-07-31 | RARE Feb avg: 3.08% median: -1.05% win: 25% σ: 9.51% n: 4 2022-04-12 → 2026-07-31 | RARE Mar avg: -11.42% median: -10.15% win: 0% σ: 2.83% n: 4 2022-04-12 → 2026-07-31 | RARE Apr avg: 2.94% median: 7.65% win: 60% σ: 12.34% n: 5 2022-04-12 → 2026-07-31 | RARE May avg: -8.40% median: -5.64% win: 20% σ: 16.97% n: 5 2022-04-12 → 2026-07-31 | RARE Jun avg: 13.88% median: 6.85% win: 80% σ: 18.92% n: 5 2022-04-12 → 2026-07-31 | RARE Jul avg: -11.59% median: -10.69% win: 20% σ: 14.49% n: 5 2022-04-12 → 2026-07-31 | RARE Aug avg: 2.65% median: -0.41% win: 50% σ: 18.91% n: 4 2022-04-12 → 2026-07-31 (current) | RARE Sep avg: -4.51% median: -2.63% win: 25% σ: 5.96% n: 4 2022-04-12 → 2026-07-31 | RARE Oct avg: 0.96% median: -1.50% win: 25% σ: 9.92% n: 4 2022-04-12 → 2026-07-31 | RARE Nov avg: -1.67% median: -3.08% win: 50% σ: 8.82% n: 4 2022-04-12 → 2026-07-31 | RARE Dec avg: 1.31% median: 5.71% win: 50% σ: 29.27% n: 4 2022-04-12 → 2026-07-31 |